keyword
MENU ▼
Read by QxMD icon Read
search

Price transparency

keyword
https://www.readbyqxmd.com/read/29124937/an-implantable-transparent-conductive-film-with-water-resistance-and-ultra-bendability-for-electronic-devices
#1
Youngjun Song, Sejung Kim, Michael J Heller
Recently, instead of indium tin oxide (ITO), the random mesh pattern of metallic nanowires for flexible transparent conducting electrodes (FTCEs) has received a great amount of interest due to its flexibility, low resistance, reasonable price and compliant processes. Mostly, nanowires for FTCEs are fabricated by spray or mayer coating methods. However, the metallic nanowires layer of FTCEs, which is fabricated by these methods, has spiked surface roughness and low junction contact between the nanowires that leads to their high sheet resistance value...
November 10, 2017: ACS Applied Materials & Interfaces
https://www.readbyqxmd.com/read/29124745/medication-access-in-america-and-medicare-part-d-rx-shopping-saves-but-may-be-costly
#2
Gina Upchurch, Marilyn E Disco, Jessica L Visco, Katie F Huffman
This article is a reflection of some of the changes we have witnessed in pharmacy over the years, including the rise in medication usage and prices and the transformation of how medicines are paid for in the U.S., with growing concern over pricing transparency. We discuss the complex Medicare Part D prescription drug benefit, how enrollees can save by comparing plans annually, and the influence of preferred pharmacies. We review options for medication assistance other than Part D and share our belief that while Medicare Part D has dramatically improved access to medicines, more needs to be done to decrease Medicare's and individuals' out-of-pocket spending, and as importantly, to ensure that medicines are doing more good than harm...
November 9, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29033060/a-review-of-international-coverage-and-pricing-strategies-for-personalized-medicine-and-orphan-drugs
#3
REVIEW
Irina Degtiar
BACKGROUND: Personalized medicine and orphan drugs share many characteristics-both target small patient populations, have uncertainties regarding efficacy and safety at payer submission, and frequently have high prices. Given personalized medicine's rising importance, this review summarizes international coverage and pricing strategies for personalized medicine and orphan drugs as well as their impact on therapy development incentives, payer budgets, and therapy access and utilization...
September 29, 2017: Health Policy
https://www.readbyqxmd.com/read/28955404/responsible-pricing-in-value-based-assessment-of-cancer-drugs-real-world-data-are-an-inevitable-addition-to-select-meaningful-new-cancer-treatments
#4
EDITORIAL
Wim van Harten, Maarten J IJzerman
Recently, NICE was given the task of governing the Cancer Drug Fund (CDF) in the UK as the latter was criticized for allowing too many insufficiently tested drugs to be covered [1, 2]. The CDF was initiated in 2012, but immediately received criticism from several health economists because of the rather strict coverage criteria that are commonly used by NICE for most other health services in the NHS. This led to questions about the use of different reimbursement criteria (why have a different fund otherwise?) for expensive cancer drugs...
2017: Ecancermedicalscience
https://www.readbyqxmd.com/read/28945173/insulin-degludec-versus-insulin-glargine-u100-for-patients-with-type-1-or-type-2-diabetes-in-the-us-a-budget-impact-analysis-with-rebate-tables
#5
Wendy S Lane, James Weatherall, Jens Gundgaard, Richard F Pollock
BACKGROUND AND AIMS: Drug rebates are almost universally negotiated privately between the manufacturer and the payer in the US. The aim of the present study was to illustrate the use of a "rebate table" to improve the transparency and utility of published budget impact analyses in the US by modeling ranges of hypothetical rebates for two comparators. Worked examples were conducted to illustrate the budgetary implications of using insulin degludec (IDeg) relative to insulin glargine (IGlar) U100 in patients with type 1 or 2 diabetes...
October 12, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28944731/the-fda-unapproved-drugs-initiative-an-observational-study-of-the-consequences-for-drug-prices-and-shortages-in-the-united-states
#6
Ravi Gupta, Sanket S Dhruva, Erin R Fox, Joseph S Ross
BACKGROUND: Hundreds of drug products are currently marketed in the United States without approval from the FDA. The 2006 Unapproved Drugs Initiative (UDI) requires manufacturers to remove these drug products from the market or obtain FDA approval by demonstrating evidence of safety and efficacy. Once the FDA acts against an unapproved drug, fewer manufacturers remain in the market, potentially enabling drug price increases and greater susceptibility to drug shortages. There is a need for systematic study of the UDI's effect on prices and shortages of all targeted drugs...
October 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/28929871/japanese-healthcare-fostering-competition-and-controlling-costs
#7
James H Tiessen, Ken Kato
Japan's universal healthcare system is relatively inexpensive, provides accessible services, and was established nearly 10 years before Canada's. Two aspects of Japan's system are particularly interesting. The first is that there is active competition for patients between a variety of hospital providers, which can be privately or publicly owned. This competition is based on service quality because prices are set centrally. The second feature is that these prices are adjusted biannually by a National Council, the Chuikyo, that includes payers (employers), providers, and third-party experts in public negotiations...
July 2017: Healthcare Management Forum
https://www.readbyqxmd.com/read/28917469/prior-authorizations-for-dermatologic-medications-an-american-academy-of-dermatology-survey-of-us-dermatology-providers-and-staff
#8
LETTER
Aaron M Secrest, Maryam M Asgari, Arianne S Kourosh, John S Barbieri, Joerg Albrecht
No abstract text is available yet for this article.
October 2017: Journal of the American Academy of Dermatology
https://www.readbyqxmd.com/read/28892524/research-and-development-spending-to-bring-a-single-cancer-drug-to-market-and-revenues-after-approval
#9
Vinay Prasad, Sham Mailankody
Importance: A common justification for high cancer drug prices is the sizable research and development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of R&D spending is $2.7 billion (2017 US dollars). However, this analysis lacks transparency and independent replication. Objective: To provide a contemporary estimate of R&D spending to develop cancer drugs. Design, Setting, and Participants: Analysis of US Securities and Exchange Commission filings for drug companies with no drugs on the US market that received approval by the US Food and Drug Administration for a cancer drug from January 1, 2006, through December 31, 2015...
November 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28874405/pediatric-price-transparency-time-to-come-out-of-the-dark
#10
Kirsten Nieto, Christopher Moriates
No abstract text is available yet for this article.
September 5, 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28874404/pediatric-price-transparency-still-opaque-with-opportunities-for-improvement
#11
Laura J Faherty, Charlene A Wong, Jordyn Feingold, Joan Li, Robert Town, Evan Fieldston, Rachel M Werner
OBJECTIVES: Price transparency is gaining importance as families' portion of health care costs rise. We describe (1) online price transparency data for pediatric care on children's hospital Web sites and state-based price transparency Web sites, and (2) the consumer experience of obtaining an out-of-pocket estimate from children's hospitals for a common procedure. METHODS: From 2015 to 2016, we audited 45 children's hospital Web sites and 38 state-based price transparency Web sites, describing availability and characteristics of health care prices and personalized cost estimate tools...
September 5, 2017: Hospital Pediatrics
https://www.readbyqxmd.com/read/28859183/association-between-patient-value-systems-and-physician-and-practice-attributes-available-online
#12
Jamie L Welshhans, Jeffrey J Harmon, Ira Papel, Richard Gentile, Devinder Mangat, Patrick Byrne, Ryan M Collar
Importance: The relative value of facial plastic surgeon personal and practice attributes is relevant to the broader health care system because of increasing out-of-pocket expenses to patients. Objective: To determine the relative value of specific facial plastic surgeon personal and practice attributes available online from the perspective of patients. Design, Setting, and Participants: This study consisted of an electronic survey sent to patients by email using choice-based conjoint analysis; surveys were sent between December 2015 and March 2016...
August 31, 2017: JAMA Facial Plastic Surgery
https://www.readbyqxmd.com/read/28836222/the-implementation-of-managed-entry-agreements-in-central-and-eastern-europe-findings-and-implications
#13
Alessandra Ferrario, Diāna Arāja, Tomasz Bochenek, Tarik Čatić, Dávid Dankó, Maria Dimitrova, Jurij Fürst, Ieva Greičiūtė-Kuprijanov, Iris Hoxha, Arianit Jakupi, Erki Laidmäe, Olga Löblová, Ileana Mardare, Vanda Markovic-Pekovic, Dmitry Meshkov, Tanja Novakovic, Guenka Petrova, Maciej Pomorski, Dominik Tomek, Luka Voncina, Alan Haycox, Panos Kanavos, Patricia Vella Bonanno, Brian Godman
BACKGROUND: Managed entry agreements (MEAs) are a set of instruments to facilitate access to new medicines. This study surveyed the implementation of MEAs in Central and Eastern Europe (CEE) where limited comparative information is currently available. METHOD: We conducted a survey on the implementation of MEAs in CEE between January and March 2017. RESULTS: Sixteen countries participated in this study. Across five countries with available data on the number of different MEA instruments implemented, the most common MEAs implemented were confidential discounts (n = 495, 73%), followed by paybacks (n = 92, 14%), price-volume agreements (n = 37, 5%), free doses (n = 25, 4%), bundle and other agreements (n = 19, 3%), and payment by result (n = 10, >1%)...
August 23, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28817296/patients-views-on-price-shopping-and-price-transparency
#14
Hannah L Semigran, Rebecca Gourevitch, Anna D Sinaiko, David Cowling, Ateev Mehrotra
OBJECTIVES: Driven by the growth of high deductibles and price transparency initiatives, patients are being encouraged to search for prices before seeking care, yet few do so. To understand why this is the case, we interviewed individuals who were offered access to a widely used price transparency website through their employer. STUDY DESIGN: Qualitative interviews. METHODS: We interviewed individuals enrolled in a preferred provider organization product through their health plan about their experience using the price transparency tool (if they had done so), their past medical experiences, and their opinions on shopping for care...
June 1, 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28812229/economics-and-cost-effectiveness-of-multiple-sclerosis-therapies-in-the-usa
#15
REVIEW
Daniel M Hartung
Multiple sclerosis (MS) is a disabling, chronic disease that imposes a significant economic burden on patients and the US healthcare system. The largest cost component for individuals with MS are prescription drugs, specifically disease-modifying therapies (DMTs). Despite an increase in the number and diversity of DMTs over the past 10 years, acquisition costs for all DMTs have escalated dramatically at rates substantially higher than medical inflation. Currently, costs for most DMTs exceed $70,000 a year. Recent cost-effectiveness studies suggest the cost for nearly all DMTs exceeds generally accepted thresholds for what is considered a good value in the USA, even after factoring expected rebates...
August 15, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28772164/multiple-criteria-decision-analysis-mcda-for-evaluating-new-medicines-in-health-technology-assessment-and-beyond-the-advance-value-framework
#16
Aris Angelis, Panos Kanavos
Escalating drug prices have catalysed the generation of numerous "value frameworks" with the aim of informing payers, clinicians and patients on the assessment and appraisal process of new medicines for the purpose of coverage and treatment selection decisions. Although this is an important step towards a more inclusive Value Based Assessment (VBA) approach, aspects of these frameworks are based on weak methodologies and could potentially result in misleading recommendations or decisions. In this paper, a Multiple Criteria Decision Analysis (MCDA) methodological process, based on Multi Attribute Value Theory (MAVT), is adopted for building a multi-criteria evaluation model...
September 2017: Social Science & Medicine
https://www.readbyqxmd.com/read/28751712/activation-of-mitophagy-leads-to-decline-in-mfn2-and-loss-of-mitochondrial-mass-in-fuchs-endothelial-corneal-dystrophy
#17
Anne-Sophie Benischke, Shivakumar Vasanth, Takashi Miyai, Kishore Reddy Katikireddy, Tomas White, Yuming Chen, Adna Halilovic, Marianne Price, Francis Price, Paloma B Liton, Ula V Jurkunas
Human corneal endothelial cells (HCEnCs) are terminally differentiated cells that have limited regenerative potential. The large numbers of mitochondria in HCEnCs are critical for pump and barrier function required for corneal hydration and transparency. Fuchs Endothelial Corneal Dystrophy (FECD) is a highly prevalent late-onset oxidative stress disorder characterized by progressive loss of HCEnCs. We previously reported increased mitochondrial fragmentation and reduced ATP and mtDNA copy number in FECD. Herein, carbonyl cyanide m-chlorophenyl hydrazone (CCCP)-induced mitochondrial depolarization decreased mitochondrial mass and Mfn2 levels, which were rescued with mitophagy blocker, bafilomycin, in FECD...
July 27, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28742372/health-care-price-transparency-and-communication-implications-for-radiologists-and-patients-in-an-era-of-expanding-shared-decision-making
#18
Gelareh Sadigh, Ruth C Carlos, Elizabeth A Krupinski, Carolyn C Meltzer, Richard Duszak
OBJECTIVE: The purpose of this article is to review the literature on communicating transparency in health care pricing, both overall and specifically for medical imaging. Focus is also placed on the imperatives and initiatives that will increasingly impact radiologists and their patients. CONCLUSION: Most Americans seek transparency in health care pricing, yet such discussions occur in fewer than half of patient encounters. Although price transparency tools can help decrease health care spending, most are used infrequently and most lack information about quality...
November 2017: AJR. American Journal of Roentgenology
https://www.readbyqxmd.com/read/28741264/why-are-diabetes-medications-so-expensive-and-what-can-be-done-to-control-their-cost
#19
REVIEW
Laura N McEwen, Sarah Stark Casagrande, Shihchen Kuo, William H Herman
PURPOSE OF REVIEW: The purposes of this study were to describe how medication prices are established, to explain why antihyperglycemic medications have become so expensive, to show trends in expenditures for antihyperglycemic medications, and to highlight strategies to control expenditures in the USA. RECENT FINDINGS: In the U.S., pharmaceutical manufacturers set the prices for new products. Between 2002 and 2012, expenditures for antihyperglycemic medications increased from $10 billion to $22 billion...
September 2017: Current Diabetes Reports
https://www.readbyqxmd.com/read/28740622/drug-pricing-and-reimbursement-information-management-processes-and-decision-making-in-the-global-economy
#20
Dimitrios Tsourougiannis
Background: Cost-containment initiatives are re-shaping the pharmaceutical business environment and affecting market access as well as pricing and reimbursement decisions. Effective price management procedures are too complex to accomplish manually. Prior to February 2013, price management within Astellas Pharma Europe Ltd was done manually using an Excel database. The system was labour intensive, slow to update, and prone to error. An innovative web-based pricing information management system was developed to address the shortcomings of the previous system...
2017: Journal of Market Access & Health Policy
keyword
keyword
80684
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"